Forty-Seventh Board Meeting

<p>Mišo Pejković from the Eastern Europe and Central Asia Constituency is designated as Rapporteur for the 47th Board Meeting.</p>

<p>The Agenda for the 47th Board Meeting (GF/B47/01) is approved.</p>

<ol> <li>Based on the recommendation of the Strategy Committee, the Board approves the revised Eligibility Policy, as set forth in Annex 1 to GF/B47/02 (the “Revised Eligibility Policy”).</li> <li>Accordingly, the Board: <ol type="i"> <li>Acknowledges that this decision point and the Revised Eligibility Policy supersede the decision point GF/B39/DP03 and the previous Eligibility Policy as set forth in Annex 1 to GF/B39/02 (the “Previous Eligibility Policy”); and</li> <li>Notes that, notwithstanding paragraph 2.i of this decision point, the Previous Eligibility Policy remains applicable to grant programs originating from the 2020-2022 allocation period.</li> </ol> </li> </ol>

<p>Based on the recommendation of the Strategy Committee, the Board approves the eligibility of the six (6) Transition Funding components from the 2020-2022 allocation period for an additional allocation of Transition Funding for the 2023-2025 allocation period.</p>

<ol> <li>The Board notes:<br /> <ol type="a"> <li>Its decision in May 2019 (GF/B41/DP03) that (i) established the allocation methodology for the 2020 - 2022 allocation period; and (ii) acknowledged the technical parameters for the 2020 - 2022 allocation period; and</li> <li>The decision by the Strategy Committee (the “SC”) in March 2022 GF/SC18/DP05, under authority delegated by the Board, to establish technical parameters for the 2023 – 2025 allocation period (the “Technical Parameters”).</li> </ol> </li> <li>Accordingly, based on the recommendations of the SC, as presented in GF/B47/03, the Board:<br /> <ol type="a"> <li>Approves the allocation methodology presented in Annex 1 to GF/B47/03 (the “Allocation Methodology”);</li> <li>Acknowledges the Technical Parameters for the 2023 – 2025 allocation period, as presented in Annex 2 to GF/B47/03 and</li> <li>Approves that no more than 7.5% of the total sources of funds available for country allocations be used to ensure scale-up, impact and paced reductions, as described in paragraph 4.c of the Allocation Methodology; and</li> </ol> </li> <li>Accordingly, the Board:<br /> <ol type="a"> <li>Requests the SC to review and approve, at its July 2022 meeting, the method by which the Secretariat will apply and report on the qualitative adjustment process; and</li> <li>Acknowledges that the Allocation Methodology and Technical Parameters shall apply for the 2023– 2025 allocation period and supersede the 2020 – 2022 allocation methodology and technical parameters presented in GF/B41/02.</li> </ol> </li> </ol>

<p>Based on the recommendation of the Strategy Committee, as presented in GF/B4704 – Revision 1, the Board:</p> <ol> <li>Acknowledges that the total amount of sources of funds for allocation for the 2023-2025 allocation period will be decided by the Board in November 2022, based on the recommendation of the Audit and Finance Committee following announced replenishment results from the 7th Replenishment;</li> <li>Approves that the total amount of funding for catalytic investments in the 2023-2025 allocation period (“Catalytic Investments”) will be determined by the total amount of sources of funds for allocation for the 2023-2025 allocation period;</li> <li>Approves Catalytic Investments for the 2023 –2025 allocation period, based on the total amount of sources of funds for allocation, as set forth in Table 1 of GF/B47/DP06;</li> <li>Agrees that in the event that sources of funds for allocation for the 2023-2025 allocation period are above the midpoint of the funding range specified for any scenario in Table 1 of GF/B47/DP06, the Secretariat may recommend to the Board to approve additional amounts for Catalytic Investments (up to 50% of the difference in total catalytic funding for the applicable scenario and the next higher funding scenario) to be invested in the priority areas for the next higher funding scenario in Table 1 of GF/B47/DP06;</li> <li>Acknowledging that additional refinements may be required to the catalytic investment amounts for the priorities under the “RSSH/Cross-Cutting” section of Table 1 to GF/B47/DP06, delegates authority to the Strategy Committee to approve, within such RSSH/Cross-Cutting section (with the exclusion of the Emergency Fund priority): (i) a decrease in the amount of any priority by up to 15% and (ii) the inclusion of such decreased amounts within another priority in this group. Any changes made under this paragraph will be approved by the Strategy Committee at its July 2022 meeting, and will be informed by input to be provided by the Secretariat as described in paragraph 6.ii below</li> <li>Approves that the Secretariat will:<br /> <ol type="i"> <li>operationalize Catalytic Investments, considering TRP and TERG recommendations as well as available program and financial performance data from ongoing catalytic investments, and work with partners to ensure that Catalytic Investments have clear objectives, expected outcomes and impact and transparency in the investment decisions on geographic prioritization and country selection;</li> <li>update the Strategy Committee, at its July 2022 meeting, on the status of such operationalization and planned next steps, and report, bi-annually, to the Strategy Committee and Board thereafter on further operationalization;</li> <li>have flexibility, within the total amount of funding for Catalytic Investments, to increase or decrease the amount for any approved priority up to 15% and report to the Strategy Committee on any such changes; and</li> <li>present any increase or decrease of an amount for any approved priority above 15% to the Strategy Committee for approval; and</li> </ol> </li> <li>Agrees that the Secretariat will have delegated authority to increase the amount of funding available for the Emergency Fund, by up to 50% of the amount approved for this priority, using funding approved as available by the Audit and Finance Committee for portfolio optimization, and that paragraph 6.iv above will not apply to increases to the Emergency Fund. Any increase above 50% will be presented to the Board for its urgent, no-objection approval.</li> </ol>

<p>The Board approves the amendments to the (i) Terms of Reference Chair and Vice-Chair of<br />the Board of the Global Fund, (ii) Bylaws of the Global Fund; and (iii) the Operating Procedures of the Board and Committees of the Global Fund, set out respectively in annexes 1, 2 and 3 to GF/B47/05.</p>

<p>Based on the recommendation of the Ethics and Governance Committee (the “EGC”), as presented in GF/B47/06 – Revision 1, the Board:</p> <ol> <li>Acknowledges the changes to the Charter of the Strategy Committee already approved through GF/B46/DP06 and which will be effective as of 31 December 2022;</li> <li>Amends the Charters of the Standing Committees of the Board (“the Charters”), as set forth respectively in Annexes 5, 6 and 7 of GF/B47/06 – Revision 1, which shall each become effective upon the conclusion of the forty-seventh Board meeting; and</li> <li>Acknowledging the specific scope and intent of the changes to the Charters, requests the EGC leadership to determine, after consultation with the Board leadership, Coordinating Group, Standing Committees and Secretariat, as relevant, whether a more complete review of the Charters may be required during the next EGC term.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituentgrants, as listed in Table 1 of GF/B47/ER01 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by theproposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemedappropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and(b)shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding availablefor each country disease component among its constituent grants, provided that the TechnicalReview Panel (the “TRP”) validates any redistribution that constitutes a material change fromthe program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 2 of GF/B47/ER02(“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceilingamount that may be available for the relevant implementation period of each country diseasecomponent’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding availablefor each country disease component among its constituent grants, provided that the TechnicalReview Panel (the “TRP”) validates any redistribution that constitutes a material change fromthe program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board approves the appointment of Magda Robalo Correia e Silva as Vice-Chair of the Ethics and Governance Committee, to commence her term on 23 May 2022 and serve for three years or until appointment of her successor (whichever is earlier).</p>

<p>The Board approves a modification to the mandate and functions of the Office of the Inspector General through a change to the Charter of the Office of the Inspector General (the “OIG Charter”), as revised and set forth in Annex 1 to GF/B47/EDP04.</p>

<p>Based on the recommendation of the EGC, the Board approves the amendments tothe Operating Procedures of the Board and Committees of the Global Fund, as set out in Annex 2 to GF/B47/ER04. The amendments to the BCOP shall enter into force upon the adoption of this decision point.</p>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B47/ER05 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B47/ER06 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board approves the appointment of Susanne Kuehn to serve as the next Global Fund Ethics Officer for a three-year term which can be renewed no more than once.</p>

<p>The Board approves the Report of the Global Fund 47th Board Meeting, as set forth in GF/B47/22.</p>

<p>Based on the recommendation of the Strategy Committee described in [GF/B47/ER08], the Board:</p> <ol> <li>Acknowledges that the Eligibility Policy (GF/B47/03) allows certain non-eligible countries to be recommended to be exceptionally eligible for malaria in line with paragraph 11 of the Policy;</li> <li>Acknowledges that the Eligibility Policy’s treatment of Venezuela’s exceptional tuberculosis (“TB”) eligibility must consider the fact that Venezuela is the only country in the World Bank’s classification system that is temporarily unclassified;</li> <li>Based on the Secretariat and technical partners’ recommendation described in [GF/B47/ER08], approves that Venezuela’s malaria and TB components be made exceptionally eligible for the 2023-2025 Allocation period; and</li> <li>Notes that any components made exceptionally eligible will be governed by the Allocation Methodology 2023-2025 and existing Global Fund policies and processes.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituentgrants, as listed in Table 1 of GF/B47/ER09 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by theproposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemedappropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and(b)shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding availablefor each country disease component among its constituent grants, provided that the TechnicalReview Panel (the “TRP”) validates any redistribution that constitutes a material change fromthe program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 2 of GF/B47/ER09(“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceilingamount that may be available for the relevant implementation period of each country diseasecomponent’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding availablefor each country disease component among its constituent grants, provided that the TechnicalReview Panel (the “TRP”) validates any redistribution that constitutes a material change fromthe program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<ol> <li>The Board notes the recommendation of the Ethics and Governance Committee, as set forth in GF/B47/ER10, relating to the membership of the Board Leadership Nomination Committee (“Nomination Committee”).</li> <li>Accordingly, the Board appoints the following individuals to serve as members of the Nomination Committee in accordance with the terms of reference of the Nomination Committee approved under electronic decision point GF/B39/EDP08 and set out in Annex 4 to GF/B39/ER07: <ol type="a"> <li>Grace Rwakarema, Chair of the Nomination Committee;</li> <li>Sherwin Charles, Vice-Chair of the Nomination Committee;</li> <li>Cecilia Senoo, Member;</li> <li>Heiko Warnken, Member;</li> <li>Fiu Williame-Igara, Member;</li> <li>Mamadi Yilla, Member; and,</li> <li>Ren Minghui, Member.</li> </ol> </li> </ol>

<p>Based on the recommendation of the Strategy Committee, the Board approves the revision to Key Performance Indicator 4 as presented in GF/B47/ER11.</p>

<p>The Board approves the appointment of:</p> <ol> <li>Harriet Ludwig, representing the Germany Constituency, as a voting member of the Strategy Committee for a term that will expire on May 2025, or until the appointment of her successor;</li> <li>Rouksana Simjee, to serve in her personal capacity as a voting member of the Ethics and Governance Committee for a term that will expire on May 2025, or until the appointment of her successor.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 1 of GF/B47/ER13 (“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceilingamount that may be available for the relevant implementation period of each country diseasecomponent’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding availablefor each country disease component among its constituent grants, provided that the TechnicalReview Panel (the “TRP”) validates any redistribution that constitutes a material change fromthe program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board reaffirms the importance of responding efficiently and rapidly to emergency situations to ensure the continuity of life-saving health services delivered through Global Fund-supported programs. The Board recognizes the devastating impact that recent natural disasters, climate-related events, and ongoing and protracted conflicts such as those in Pakistan, Ukraine, and Somalia have had on the health and well-being of people supported by Global Fund programs and reaffirms the importance of the Emergency Fund in rapidly responding to such contexts.</p> <p>Therefore, the Board approves the reallocation of USD $ 40 million from Audit and Finance Committee (AFC)-approved portfolio optimization funds to the Emergency Fund.</p>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituentgrants, as listed in Table 1 of GF/B47/ER15 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by theproposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemedappropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and(b)shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding availablefor each country disease component among its constituent grants, provided that the TechnicalReview Panel (the “TRP”) validates any redistribution that constitutes a material change fromthe program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 2 of GF/B47/ER15 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding availablefor each country disease component among its constituent grants, provided that the TechnicalReview Panel (the “TRP”) validates any redistribution that constitutes a material change fromthe program and funding request initially reviewed and recommended by the TRP.</li> </ol>